Camp4 Therapeutics Amends 2024 Equity Plan, Adopts 2026 Inducement Plan

Camp4 Therapeutics' stockholders approved an amendment to the 2024 Equity Incentive Plan, modifying the evergreen provision to include pre-funded warrants in the calculation of the annual share increase. Concurrently, the Board adopted a new 2026 Inducement Plan, authorizing up to 500,000 shares for various stock-based awards to attract and retain employees, without requiring stockholder approval per Nasdaq rules. Additionally, at the Annual Meeting, stockholders elected three Class II directors and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026.